Entrada Therapeutics (TRDA) Cash & Current Investments (2022 - 2025)
Historic Cash & Current Investments for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $93.3 million.
- Entrada Therapeutics' Cash & Current Investments rose 1952.24% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 1952.24%. This contributed to the annual value of $101.2 million for FY2024, which is 4971.6% up from last year.
- Entrada Therapeutics' Cash & Current Investments amounted to $93.3 million in Q3 2025, which was up 1952.24% from $72.5 million recorded in Q2 2025.
- Entrada Therapeutics' 5-year Cash & Current Investments high stood at $263.9 million for Q1 2022, and its period low was $45.2 million during Q4 2022.
- Over the past 4 years, Entrada Therapeutics' median Cash & Current Investments value was $79.7 million (recorded in 2023), while the average stood at $124.2 million.
- Per our database at Business Quant, Entrada Therapeutics' Cash & Current Investments plummeted by 7593.29% in 2023 and then skyrocketed by 13231.26% in 2024.
- Quarter analysis of 4 years shows Entrada Therapeutics' Cash & Current Investments stood at $45.2 million in 2022, then soared by 49.7% to $67.6 million in 2023, then skyrocketed by 49.72% to $101.2 million in 2024, then dropped by 7.83% to $93.3 million in 2025.
- Its last three reported values are $93.3 million in Q3 2025, $72.5 million for Q2 2025, and $67.8 million during Q1 2025.